BEIJING (Reuters) – China will use its national drug bulk-buy scheme to lower the price of drugs currently sold at higher prices compared with other markets, it said in an official statement. The move could force international drugmakers to further cut prices and enable copycat medicines to replace imported off-patent brands at faster pace. Many… Read More »
Hong Kong billionaire Li Ka-shing at the listing press conference for CK Life Sciences International (Holdings). K. Y. Cheng | South China Morning Post | Getty Images Shares of biotech company CK Life Sciences soared more than 200% last week on news that the Hong Kong-based firm has made significant headway in a skin cancer… Read More »
Matthew Freeby, MD, director, Gonda Diabetes Center, David Geffen School of Medicine, UCLA. Gerald Bernstein, MD, program coordinator, Friedman Diabetes Institute, Lenox Hill Hospital, New York. AstraZeneca: Press release, Oct. 21, 2019. The New England Journal of Medicine, Jan. 24, 2019. Invokana web site. GoodRx. WebMD Health
NEW YORK (Reuters) – Merck & Co Chief Executive Ken Frazier said on Thursday a rule to base the price the U.S. government pays for some prescription drugs in it Medicare program on lower prices in other countries would face legal challenges if adopted. FILE PHOTO: Ken Frazier, Chairman and CEO, Merck & Co., speaks… Read More »
Leonard S. Schleifer, president and chief executive officer of Regeneron Pharmaceuticals Inc., speaks during the Bloomberg “Focus on Pharma” event in New York City on June 29, 2016. Schleifer discussed the need for the pharmaceutical industry to do a better job explaining the value proposition of products they bring out and the need to price… Read More »